A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Efficacy of GLS-012 Monotherapy and in Combination With GLS-010 in Patients With Advanced Solid Tumors After Progression on Standard Treatment (Triumph-01)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GLS-012 (Primary) ; Zimberelimab (Primary)
Indications Malignant melanoma; Solid tumours
Focus Adverse reactions
Acronyms Triumph-01
Sponsors Guangzhou Gloria Biosciences

Most Recent Events

22 Jun 2023 New trial record
12 Jun 2023 According to a Guangzhou Gloria Biosciences media release, Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has cleared Investigational New Drug (IND) application for GLS-012, for treatment of malignant melanoma.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight